Literature DB >> 2648581

A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.

W R Vogler1, E Velez-Garcia, G Omura, M Raney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2648581

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  3 in total

Review 1.  Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1993-10       Impact factor: 4.981

2.  Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.

Authors:  P J Lobo; R L Powles; A Hanrahan; D K Reynold
Journal:  BMJ       Date:  1991-02-09

3.  Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015.

Authors:  Rosane Bittencourt; Teresa Cristina Bortolheiro; Maria de Lourdes Lopes Ferrari Chauffaille; Evandro Maranhão Fagundes; Katia Borgia Barbosa Pagnano; Eduardo Magalhães Rego; Wanderley Marques Bernardo
Journal:  Rev Bras Hematol Hemoter       Date:  2016-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.